HIV-Lipodystrophy
HIV-associated lipodystrophy is a syndrome of body-fat redistribution that develops in HIV-infected patients on antiretroviral therapy, characterized by excess visceral abdominal fat and peripheral subcutaneous fat loss. Tesamorelin (Egrifta®, Egrifta SV®) is FDA-approved specifically for reducing excess abdominal fat in this population.
